Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Table 3

Adverse reactions.

Grade, n (%)
Adverse events	Grades 1 (%)	Grades 2 (%)	Grades 3 (%)	Grades 4 (%)	Grades 5 (%)
Total
Abdominal pain	41 (47)	17 (20)	2 (2)	0	0
Fever	37 (43)	9 (10)	0	0	0
Vomiting	15 (17)	2 (2)	0	0	0
Hand-foot skin reactions	9 (10)	2 (2)	4 (2)	0	0
Appetite decrease	14 (16)	0	0	0	0
Increased ALT/AST	12 (14)	3 (3)	0	0	0
Diarrhea	7 (8)	1 (1)	1 (1)	0	0
Hypertension	9 (10)	5 (6)	1	0	0
Fatigue	10 (11)	2 (2)	0	0	0
Proteinuria	12 (14)	4 (5)	3 (3)	0	0
Headache	7 (8)	1 (1)	0	0	0
Nausea	6 (7)	1 (1)	0	0	0
Oral ulcer	3 (3)	0	0	0	0
Gastrointestinal hemorrhage	2 (2)	2 (2)	0	0	0

National Cancer Institute CTCAE version 4.03 uses grades 1 through 5 to refer to the severity of the adverse events, based on general guidelines. Grade 1, mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated. Grade 2, moderate, minimal, local, or noninvasive intervention indicated. Grade 3, severe, medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling. Grade 4, life-threatening, urgent intervention indicated. Grade 5, death, related to adverse event. CTCAE, Common Terminology Criteria for Adverse Event.